SI2370440T1 - 8-kloro-3-pentil-3,7-dihidro-1h-purin-2,6-dion 2-amino-2(hidroksimetil)-1,3-propandiol anhidrat za zdravljenje bolezni - Google Patents

8-kloro-3-pentil-3,7-dihidro-1h-purin-2,6-dion 2-amino-2(hidroksimetil)-1,3-propandiol anhidrat za zdravljenje bolezni

Info

Publication number
SI2370440T1
SI2370440T1 SI200931113T SI200931113T SI2370440T1 SI 2370440 T1 SI2370440 T1 SI 2370440T1 SI 200931113 T SI200931113 T SI 200931113T SI 200931113 T SI200931113 T SI 200931113T SI 2370440 T1 SI2370440 T1 SI 2370440T1
Authority
SI
Slovenia
Prior art keywords
anhydrate
dione
purine
propanediol
dihydro
Prior art date
Application number
SI200931113T
Other languages
English (en)
Inventor
Holly Esken
Beth Adams Norton
Original Assignee
Glaxosmithkline Llc Cooperation Service Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc Cooperation Service Company filed Critical Glaxosmithkline Llc Cooperation Service Company
Publication of SI2370440T1 publication Critical patent/SI2370440T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200931113T 2008-12-08 2009-12-07 8-kloro-3-pentil-3,7-dihidro-1h-purin-2,6-dion 2-amino-2(hidroksimetil)-1,3-propandiol anhidrat za zdravljenje bolezni SI2370440T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12059608P 2008-12-08 2008-12-08
PCT/US2009/066941 WO2010068581A1 (en) 2008-12-08 2009-12-07 Novel compounds
EP09832421.3A EP2370440B1 (en) 2008-12-08 2009-12-07 8-Chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione 2-amino-2-(hydroxymethyl)-1,3-propanediol anhydrate for the treatment of diseases

Publications (1)

Publication Number Publication Date
SI2370440T1 true SI2370440T1 (sl) 2015-02-27

Family

ID=42243044

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200931113T SI2370440T1 (sl) 2008-12-08 2009-12-07 8-kloro-3-pentil-3,7-dihidro-1h-purin-2,6-dion 2-amino-2(hidroksimetil)-1,3-propandiol anhidrat za zdravljenje bolezni

Country Status (22)

Country Link
US (3) US9163024B2 (sl)
EP (1) EP2370440B1 (sl)
JP (1) JP5666464B2 (sl)
KR (1) KR101743783B1 (sl)
CN (1) CN102245606B (sl)
AU (1) AU2009324811B2 (sl)
BR (1) BRPI0922134A2 (sl)
CA (1) CA2746316C (sl)
CY (1) CY1116032T1 (sl)
DK (1) DK2370440T3 (sl)
EA (1) EA020037B1 (sl)
ES (1) ES2527354T3 (sl)
HR (1) HRP20150026T1 (sl)
IL (1) IL213032A (sl)
MX (1) MX2011006022A (sl)
PL (1) PL2370440T3 (sl)
PT (1) PT2370440E (sl)
RS (1) RS53777B1 (sl)
SI (1) SI2370440T1 (sl)
SM (1) SMT201500012B (sl)
WO (1) WO2010068581A1 (sl)
ZA (1) ZA201103397B (sl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713982B2 (en) 2004-02-14 2010-05-11 Smithkline Beecham Corporation Xanthines with HM74A receptor activity
AR055369A1 (es) 2005-08-10 2007-08-22 Smithkline Beecham Corp Compuestos derivados de xantina, su uso para preparar un medicamento para el tratamiento de una enfermedad mediada por el receptor hm74a, formulaciones y combinacion farmaceuticas que la comprenden y metodo de preparacion de los mismos
EA201491749A1 (ru) * 2012-03-22 2015-01-30 ТРАНСТЕК ФАРМА, ЭлЭлСи Трис-(гидроксиметил)аминометановые соли низкомолекулярного агониста glp1r, их фармацевтические композиции и применение
WO2024179463A1 (zh) * 2023-02-27 2024-09-06 珊顿医药科技新加坡公司 化合物8-氯-3-戊基-3,7-二氢-1h-嘌呤-2,6-二酮的晶型及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657327A (en) 1970-06-01 1972-04-18 Upjohn Co Prostaglandin salts of tris(hydroxymethyl)aminomethane
US4647585A (en) 1984-11-08 1987-03-03 E. R. Squibb & Sons, Inc. Bicycloheptane substituted ethers
WO2001043692A2 (en) * 1999-12-15 2001-06-21 Smithkline Beecham Corporation SALTS OF Cis-4-CYANO-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]CYCLOHEXANE-1-CARBOXYLIC ACID
US20030013905A1 (en) 2002-06-10 2003-01-16 Huang Guishu Kris Salts of cis-4-cyano-4[3(cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic acid
US7713982B2 (en) * 2004-02-14 2010-05-11 Smithkline Beecham Corporation Xanthines with HM74A receptor activity
GB0423568D0 (en) * 2004-10-22 2004-11-24 Smithkline Beecham Corp Novel compounds
US20090209561A1 (en) 2004-10-22 2009-08-20 Richard Jonathan Daniel Hatley Xanthine Derivatives with HM74A Receptor Activity
AR055369A1 (es) 2005-08-10 2007-08-22 Smithkline Beecham Corp Compuestos derivados de xantina, su uso para preparar un medicamento para el tratamiento de una enfermedad mediada por el receptor hm74a, formulaciones y combinacion farmaceuticas que la comprenden y metodo de preparacion de los mismos
GB0516464D0 (en) * 2005-08-10 2005-09-14 Smithkline Beecham Corp Novel compounds

Also Published As

Publication number Publication date
EA201170783A1 (ru) 2011-12-30
ZA201103397B (en) 2012-01-25
IL213032A (en) 2015-02-26
KR20110097816A (ko) 2011-08-31
CN102245606B (zh) 2014-08-20
CY1116032T1 (el) 2017-01-25
US20110251218A1 (en) 2011-10-13
BRPI0922134A2 (pt) 2015-08-18
CA2746316A1 (en) 2010-06-17
EA020037B1 (ru) 2014-08-29
PL2370440T3 (pl) 2015-05-29
ES2527354T3 (es) 2015-01-22
SMT201500012B (it) 2015-05-03
HRP20150026T1 (hr) 2015-02-13
AU2009324811A1 (en) 2011-06-23
JP5666464B2 (ja) 2015-02-12
CA2746316C (en) 2017-01-03
JP2012511028A (ja) 2012-05-17
MX2011006022A (es) 2011-06-28
US20150366870A1 (en) 2015-12-24
EP2370440A4 (en) 2012-05-30
CN102245606A (zh) 2011-11-16
EP2370440B1 (en) 2014-11-12
US20170027945A1 (en) 2017-02-02
KR101743783B1 (ko) 2017-06-05
WO2010068581A1 (en) 2010-06-17
US9163024B2 (en) 2015-10-20
RS53777B1 (en) 2015-06-30
PT2370440E (pt) 2015-01-14
EP2370440A1 (en) 2011-10-05
AU2009324811B2 (en) 2013-01-24
IL213032A0 (en) 2011-07-31
DK2370440T3 (en) 2014-12-08

Similar Documents

Publication Publication Date Title
CY2017042I2 (el) Ενωσεις πυρρολοπυριμιδινης ως αναστολεις cdk
DK2300443T3 (da) Triazolderivater, der er anvendelige til behandling af sygdomme
BRPI0925059A2 (pt) Pirimidina substituída de compostos de purina como quinase(s) inibidoras.
BR112014028395A2 (pt) derivados 3,4-di-hidro-2h-pirido[1,2-a] pirazina-1,6-diona substituídos úteis para o tratamento de (inter alia) doença de alzheimer
ZA201105720B (en) Compounds for the treatment of hepatitis c
DK2483255T3 (da) Oxazinderivater samt deres anvendelse ved behandling af neurologiske lidelser
IL208350A0 (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
BRPI0811065A2 (pt) Indazóis 5-heteroaril substituídos como inibidores de quinase
IL205671A0 (en) Novel cyclic hydrocarbon compounds for the treatment of diseases
ZA201006752B (en) Spiro-indole derivatives for the treatment of parasitic disease
BR112012018830A2 (pt) compostos heterocíclicos como inibidores de quinase de janus
IL211556A0 (en) Process for the preparation of pramlintide
SMT201500012B (it) 8-Cloro-3-pentil-3,7-diidro-1H-purin-2,6-dione 2-amine-2-(idrossimetil)-1,3-propandiolo anidrato peril trattamento di malattie
BR112012003420A2 (pt) método de fabricação de calçado usando primer multifuncional
NO20075659L (no) Framgangsmate for tilvirkning av fyringsprodukt, samt fyringsprodukt
TH0901000513A (th) อนุพันธ์สไปโรไซคลิค แอมีดสำหรับการรักษาโรคปอด
TH0801003323A (th) สารประกอบสำหรับการบำบัดโรคตับอักเสบ c
ITBA20070031U1 (it) Puntale per calzature di sicurezza
GB0913212D0 (en) Snuff sticks